ClinTec CEO & President Shortlisted by Ernst & Young for Scottish Entrepreneur of the Year Award
News Jun 01, 2010
Post winning the IoDs Director of the Year 2010 Award (Glasgow & West of Scotland), Dr. Rabinder Buttar, has now been shortlisted by Ernst & Young for the Scottish entrepreneur of the year accolade.
Dr Rabinder Buttar of ClinTec International, the Global Clinical Research Organization, has been shortlisted by Ernst & Young for the 2010 prestigious entrepreneur of the year award.
The successful candidate will be announced in June, with the winner going through to the UK finals in London this October. The accolade is specifically designed to recognize and reward the achievements of business executives that drive the UKs most innovative enterprises. This year’s finalists’ were shortlisted according to proven ability to adapt and grow their businesses in the current challenging market conditions - exemplified by the expansion of ClinTec into 17 new countries and the achievement of 2009 global revenue growth of 45%.
Dr Buttar launched ClinTec in 1997 from her home and this year the company continued to achieve high growth and has opened further new offices as part of its expansion programme. With its fast and flexible approach to drug development, ClinTec is now present in 40 countries with a client base that includes leading brands across the biotech and pharmaceutical industries. Moreover, the company launched its first ever global academy, focussing on training clinical research personnel in the emerging markets, at the recent PABME (Pharmaceutical and Biotechnology Middle East) conference and its first 13 students successfully completed their ICH-GCP course certified by the Dubai Health Authorities.
Jim Bishop, partner and Scotland Entrepreneur of the Year leader at Ernst & Young, said: “This year’s finalists have shown their ability to adapt to market conditions by seizing opportunities and taking market share in the toughest of times. They have maintained their vision for growth and pursued it, increased their focus on customer satisfaction and loyalty, expanded into new segments and geographical markets and engaged their employees using greater communication and transparency.”
ClinTec International’s CEO, Dr Rabinder Buttar commenting on the latest ClinTec landmark, said: “This latest award is just further proof of the dramatic strides ClinTec International has made over the past year. Our fast and flexible approach to drug development is enjoying high recognition as we have expanded our international presence, grown in emerging markets and continued to harness an entrepreneurial and innovative spirit that drives our employees.”
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE